**5. Conclusions**

We are in the middle of the storm, which does not allow us to see clearly what is coming and as can be seen in **Figure 4**, the keywords *pandemic* and *coronavirus infection* are positioned in the collective unconscious. People are told they may be ready by the end of the year probably more likely to be the middle of the next year.

What is going to be the fairest outcome for both drugmakers and developing nations. The fairest outcome for the public would be that no one dies from COVID-19 because they cannot access a drug or a vaccine and the fairest outcome for drug makers would be that of the experience with COVID-19. A new era of drug development which is collaborative, open and does not have profit as the sole motive for innovation manual.

From an economics viewpoint, they are used hopefully for a short period of time to address a problem that then individuals hope to be able to move past. It is not a big moneymaker for the industry, and it is very hard to predict flu vaccines for example grown in chicken eggs, this process takes a long time and it is not as reliable as newer methods such as incubating vaccines and cells as opposed to eggs. more than 100 national influenza centers in more than 100 countries monitor the flu throughout the year and make recommendations on how to create that seasons' flu vaccines.

Society needs something else. People need a mechanism not based on the priorities of financial investors. People need a mechanism based on the priorities of public health with a long term perspective. Just summing up really briefly SARS obviously didn't change anything. Will this outbreak change something because the alarm bells were there even 20 years ago but for some reasons they were in certain places and not such a global factor. Still more coronaviruses could come along. Vaccines could become big farmers new cash cow. One of the largest pharmaceutical companies only had four special vaccine units last year. Now everyone is getting in on the act, which is great, but they are using our money and can charge what they want. Some developers promise to only charge the cost price. It could even be cheaper than the flu vaccine, it is a race everyone wants to win whoever makes the first successful COVID-19 vaccine also stands to make a fortune.

The use of vaccines has a geopolitical dimension, there is no guarantee that prices will be affordable, especially for developing countries. In the Northern Hemisphere in winter, there is likely to be a second wave in the pandemic. Is a vaccine going to be in place by then to limit the effects of a second wave? What do you think the likely outcome will be? Well, individuals do not know. Citizens know that many groups are working very hard to still develop a vaccine but no vaccine candidate has passed phase three trials yet, people do not really know, how efficacious those vaccines are going to be and therefore also how likely they will be successful.

Finally, this text recognizes that there must be autonomous action priorities for each territory, which must consist of small victories in economic, health and environmental aspects within the territory. It is also relevant to incorporate into the discussion the geopolitical influence that recognizes and encourages unequal access to vaccines, generating a gap between rich, middle-income and poor countries.

*Biotechnology to Combat COVID-19*
